Suchergebnisse - (Subject:"Siltuximab")

PubPharm (121)

71

Dose selection of siltuximab for multicentric Castleman's disease

enthalten in: Cancer chemotherapy and pharmacology | 2015

von Mayer, C. | Xie, L. | Bandekar, R. | +6

72

Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab

enthalten in: The patient | 2015

von van Rhee, F. | Rothman, M. | Ho, K. | +8

73

Interleukin-6 as a therapeutic target

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Rossi, J. | Lu, Z. | Jourdan, M. | +1

74

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma

enthalten in: International journal of hematology | 2015

von Suzuki, K. | Ogura, M. | Abe, Y. | +9

75

FDA approval : siltuximab for the treatment of patients with multicentric Castleman disease

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Deisseroth, A. | Ko, C. | Nie, L. | +11

CommentIn: Clin Cancer Res. 2015 Oct 15;21(20):4740. - PMID 26473194

76

Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response : a case report

enthalten in: Journal of medical case reports | 2015

von Mohammed, A. | Janku, F. | Qi, M. | +1

77

Reciprocal activation between IL-6/STAT3 and NOX4/Akt signalings promotes proliferation and survival of non-small cell lung cancer cells

enthalten in: Oncotarget | 2015

von Li, J. | Lan, T. | Zhang, C. | +6

78

Siltuximab : a new option for the management of Castleman's disease

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2015

von Barquero, N.

79

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

enthalten in: American journal of hematology | 2015

von Orlowski, R. | Gercheva, L. | Williams, C. | +17

80

Siltuximab (Sylvant) for treatment of multicentric castleman's disease

enthalten in: The Medical letter on drugs and therapeutics | 2015